Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 2
2005 2
2006 1
2009 1
2010 3
2011 8
2012 9
2013 3
2014 5
2015 2
2016 2
2017 9
2018 12
2019 11
2020 9
2021 7
2022 9
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY.
Oosterom N, den Braber N, Laverman GD. Oosterom N, et al. Among authors: laverman gd. Endocrinol Diabetes Metab Case Rep. 2022 Dec 1;2022:22-0292. doi: 10.1530/EDM-22-0292. Online ahead of print. Endocrinol Diabetes Metab Case Rep. 2022. PMID: 37931415 Free PMC article.
A Digital Coach (E-Supporter 1.0) to Support Physical Activity and a Healthy Diet in People With Type 2 Diabetes: Acceptability and Limited Efficacy Testing.
Hietbrink EAG, Oude Nijeweme-d'Hollosy W, Middelweerd A, Konijnendijk AAJ, Schrijver LK, Ten Voorde AS, Fokkema EMS, Laverman GD, Vollenbroek-Hutten MMR. Hietbrink EAG, et al. Among authors: laverman gd. JMIR Form Res. 2023 Jul 28;7:e45294. doi: 10.2196/45294. JMIR Form Res. 2023. PMID: 37505804 Free PMC article.
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Rotbain Curovic V, Houlind MB, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Tavenier J, Eugen-Olsen J, Laverman GD, Kooy A, Persson F, Rossing P, Heerspink HJL. Rotbain Curovic V, et al. Among authors: laverman gd. Diabetes Obes Metab. 2023 Nov;25(11):3152-3160. doi: 10.1111/dom.15209. Epub 2023 Jul 7. Diabetes Obes Metab. 2023. PMID: 37417375 Clinical Trial.
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
Laursen JC, Rotbain Curovic V, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Frimodt-Møller M, Laverman GD, Kooy A, Persson F, Heerspink HJL, Hansen CS, Rossing P. Laursen JC, et al. Among authors: laverman gd. Diabetes Obes Metab. 2023 Oct;25(10):3064-3067. doi: 10.1111/dom.15180. Epub 2023 Jun 29. Diabetes Obes Metab. 2023. PMID: 37385968 Clinical Trial. No abstract available.
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Beernink JM, Persson F, Jongs N, Laverman GD, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC, Heerspink HJL. Beernink JM, et al. Among authors: laverman gd. Diabetes Care. 2023 Mar 1;46(3):602-607. doi: 10.2337/dc22-1514. Diabetes Care. 2023. PMID: 36662635 Free PMC article. Clinical Trial.
101 results